Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Schizophrenia presents a substantial clinical and economic burden to the health-care system. In QUAlity of LIfe with AbiliFY Maintena (QUALIFY), a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), AOM 400 demonstrated...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Drugs Context
Päätekijät: Sapin, Christophe, Hartry, Ann, Kamat, Siddhesh A., Beillat, Maud, Baker, Ross A., Eramo, Anna
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Just Medical Media Limited 2016
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5035131/
https://ncbi.nlm.nih.gov/pubmed/27708677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212301
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia